TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
TRACON Pharmaceuticals (TCON) announced it will report its Q1 2022 financial and operating results after the market close on May 11, 2022. The company is focused on developing targeted cancer therapies using a cost-efficient, CRO-independent platform. It will also host a conference call to discuss these results and corporate activities. Key products in its pipeline include Envafolimab for sarcoma, YH001 for CTLA-4, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. Interested parties can access the webcast through their website.
- The company has a diverse clinical-stage pipeline with multiple candidates in development.
- Envafolimab is undergoing pivotal trials, indicating advanced progress in its development.
- None.
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, announced today that it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Wednesday, May 11, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | May 11, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 8178208 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals release its Q1 2022 financial results?
What time is the TRACON Pharmaceuticals conference call?
What are the main products in TRACON's pipeline?
How can I access the TRACON Pharmaceuticals conference call?
What are the potential benefits of TRACON's development platform?
